June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

December 11, 2014December 11, 2014

Study Finds IL-17 and IL-22 Influence Non-Melanoma Skin Cancer Growth

News

In a recent study titled “Interleukin-17 and Interleukin-22 promote tumor progression in human non-melanoma skin cancer”, published ahead of print in the European Journal of Immunology, a group of researchers from ... Read more

December 10, 2014December 10, 2014

Amgen Begins Clinical Trial To Evaluate Talimogene Laherparepvec In Combination With KEYTRUDA For Advanced Melanoma

News

Amgen has announced it will initiate a clinical trial of talimogene laherparepvec, an investigational immunotherapy, in combination with Merck’s KEYTRUDA (pembrolizumab), in patients diagnosed with regionally or distantly metastatic melanoma. ... Read more

December 9, 2014December 9, 2014

Study Reviews The Use Of Melanoma Chemopreventive Agents

News

Even though there have been significant advances in drug discovery and molecular research to identify drug targets, the incidence and mortality rates associated with melanoma have been continuously rising. Commonly ... Read more

December 8, 2014December 8, 2014

Array Signed Agreement To Regain Worldwide Rights To Binimetinib

News

Array BioPharma Inc. has announced it reached a conclusive agreement with Novartis allowing it to recover complete worldwide rights to binimetinib, a MEK inhibitor currently being investigated in three Phase ... Read more

December 5, 2014December 5, 2014

Study Finds Proteomic Biomarkers in Metastatic Melanoma

News

In a recent study titled “Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation”, published in the PlosOne journal, a team of researchers led by Dr. Vito ... Read more

December 4, 2014

Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment

News

During the 29th annual meeting of the Society for Immunotherapy of Cancer, Dr. Shari Pilon-Thomas of the Moffitt Cancer Center, presented a study titled “Efficacy of Intralesional Injection with PV-10 ... Read more

December 3, 2014December 3, 2014

Study Finds TERT Mutations Could Predict Survival Outcome in Melanoma Patients

News

In a recent study titled “TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma”, published in the Journal of the National Cancer Institute (JNCI), a group of researchers ... Read more

December 2, 2014

Study Finds immunoSEQ Assay Could Be Used to Predict Pembrolizumab Response in Melanoma Patients

News

A recent study published in Nature, successfully demonstrated that Adaptive Biotechnologies’s immunoSEQ Assay could aid in the identification of patients suffering from metastatic melanoma who are more likely to respond ... Read more

December 1, 2014December 1, 2014

Study Investigates Potent Cancer Vaccine

News

Recent research developed by scientists at the Washington University School of Medicine in St. Louis, titled “Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens” and published in the prestigious Nature ... Read more

November 28, 2014November 28, 2014

Study Finds Mechanism Behind Melanoma Patients’ Response to Pembrolizumab

News

Recent work supported by the Stand Up To Cancer (SU2C) – Cancer Research Institute (CRI) – Immunology Translational Research Dream Team, was published ahead of print in the prestigious Nature ... Read more

November 26, 2014November 26, 2014

Study Finds Key Mutations in Melanoma Patients Responsive to Immunotherapy

Melanoma, News

Timothy Chan, MD, PhD, and oncology fellow Alexandra Snyder Charen, MD, at the Memorial Sloan Kettering Cancer Center, are working to advance the way melanoma patients are treated with immunotherapy. The ... Read more

November 25, 2014November 25, 2014

Study Evaluated CT Tumor Size and Density as Predictors of Response And Outcome in Advanced Melanoma

News

In a recent study titled “Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome”, published in the Journal ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group